Americans' Rx Drug Spending Shows Rare Drop in 2012
Spending on prescription medicines in the U.S. fell for the first time in decades last year, as cash-strapped consumers continued to cut back on use of health-care services.
Lipitor
Pfizer 1Q Profit Rises, but Trims Full-Year Outlook
Pfizer reported lower-than-expected quarterly earnings and revenue and the largest U.S. drugmaker trimmed its full-year profit outlook.
Why CVS Charges $133 More Than Costco for Generic Lipitor
A Consumer Reports study finds huge price differences between retailers for generic drugs. Here's why you can save hundreds by getting your Lipitor at Costco instead of CVS.
Pfizer Sells Capsugel: Will More Asset Sales Follow?
On Monday, Pfizer announced it would sell its Capsugel business to private-equity firm KKR for $2.375 billion. If the hints the drugmaker has been giving lately are true, the move could be the start of two years of major asset sales. Here's what's ahead for the world's biggest pharmaceutical company.
Inside Wall Street: How Goldman Is Playing the Coming Tide of Generic Drugs
Generic drugs are expected to enjoy a banner year in 2011, prompting some investment pros to reformulate their portfolios to get a jump on the transition. For Goldman Sachs, that means betting on several wholesale distributors and retail drugstores that stand to benefit.
Pfizer Shrinks Its Drug Pipeline Amid R&D Cuts
In an update Tuesday, Pfizer said it is discontinuing 15 of the projects in its development pipeline. The news comes a month after the world's largest pharmaceutical company announced large research and development cuts were on the way.
Top-Selling Drugs About to Lose Patent Protection
The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.
Pfizer Joins Other Pharmas in Giving a Cautious Outlook
Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:
How to Protect Yourself From Counterfeit Drugs Online
Even if the fake drug you buy on the Web doesn't kill or even hurt you, the transaction itself can reveal your financial and medical information to questionable (at best) characters. Protecting yourself starts with understanding the dangers. Plus: Here are some helpful tips.
Pfizer's Potential Arthritis Drug Works in Late-Stage Trial
Pfizer shares were down more than 1% Monday afternoon despite the pharmaceutical giant's report Sunday of successful late-stage trial results for an experimental rheumatoid arthritis drug. The study showed tasocitinib reduced pain and inflammation and improved physical function in patients with moderately to severely active RA.
Pfizer Earnings Top Estimates, Boosts Guidance
The world's biggest drugmaker reported earnings of $4.4 billion that topped estimates but revenues of $16.2 billion fell short of expectations.
Pfizer Buys King Pharma for $3.6 Billion
With King in its fold, Pfizer -- which makes Lyrica and Celebrex -- believes it can build an industry-leading portfolio of pain relievers. Among King's most appealing entrants in that market is the new Embeda, designed to prevent misuse and abuse.
WHO Approves Pfizer's Pediatric Pneumococcus Vaccine
The World Health Organization has granted prequalification to Pfizer's Prevnar 13 pediatric vaccine, which protects against an array of pneumococcal diseases, the world's leading cause of vaccine-preventable death in children under 5. Pfizer's shares rose more than 1% Monday.